http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Amicus Therapeutics Announces Full-Year 2020 Financial Results and Corporate Updates
-
Amicus Therapeutics to Present at Upcoming Investor Conferences
-
Amicus Therapeutics to Announce Full-Year 2020 Financial Results on March 1, 2021
-
Amicus' (FOLD) AT-GAA Shows Clinically Meaningful & Significant Improvements in Both Musculoskeletal and Respiratory Measures in Late-Onset Pompe Disease Compared to Standard of Care in Pivotal Phase
-
Amicus’ AT-GAA Shows Clinically Meaningful & Significant Improvements in Both Musculoskeletal and Respiratory Measures in Late-Onset Pompe Disease Compared to Standard of Care in Pivotal Phase 3
-
Amicus Therapeutics (FOLD) Announces Positive Initial Clinical Data for CLN3 Batten Disease Gene Therapy at the 17th Annual WORLDSymposium
-
Amicus Therapeutics Presents Positive Preclinical Fabry Disease Gene Therapy Data at the 17th Annual WORLDSymposium™ 2021
-
Amicus Therapeutics Announces Positive Initial Clinical Data for CLN3 Batten Disease Gene Therapy at the 17th Annual WORLDSymposium™ 2021
-
Amicus Therapeutics Announces Presentations and Posters at the 17th Annual WORLDSymposium™ 2021
-
Amicus Therapeutics (FOLD) Announces Prelim. FY20 Revenue Outlook Above Consensus
-
Amicus Therapeutics Reports Preliminary 2020 Revenue and Provides 2021 Outlook
-
Amicus Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
-
Amicus Therapeutics Named a Great Place to Work-Certified™ Company in 2020
-
Amicus Therapeutics Appoints Michael A. Kelly to its Board of Directors
-
Amicus Therapeutics (FOLD) Initiates Rolling BLA to FDA for AT-GAA in Late-Onset Pompe Disease
-
Amicus Therapeutics Initiates Rolling Biologic License Application to the U.S. Food and Drug Administration for AT-GAA in Late-Onset Pompe Disease
-
Amicus Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Conference
-
Amicus Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Updates
-
Amicus Therapeutics to Present at the Credit Suisse 29th Annual Virtual Healthcare Conference
-
Amicus Therapeutics to Announce Third Quarter 2020 Financial Results on November 5, 2020
-
Amicus Therapeutics (FOLD) Reports Additional Positive Interim Clinical Data for CLN6 Batten Disease Gene Therapy
-
Amicus Therapeutics Announces Additional Positive Interim Clinical Data for CLN6 Batten Disease Gene Therapy at 49th Annual Meeting of the Child Neurology Society
-
Amicus Therapeutics (FOLD) Receives EMA PRIME Designation for CLN6 Batten Disease Gene Therapy
-
Amicus Therapeutics Receives European Medicines Agency PRIME Designation for CLN6 Batten Disease Gene Therapy
-
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2020
-
Amicus Therapeutics Announces Second Quarter 2020 Financial Results and Corporate Updates
-
Amicus Therapeutics to Present at the BTIG Virtual Biotechnology Conference
-
Amicus Therapeutics to Announce Second Quarter 2020 Financial Results on August 10, 2020
-
Amicus Therapeutics (FOLD) Secures $400 Million Non-Dilutive Debt Financing
-
Amicus Therapeutics Secures $400 Million Non-Dilutive Debt Financing
-
Amicus Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
-
Amicus Therapeutics Announces Virtual 2020 Annual Meeting of Shareholders
-
Amicus Therapeutics Announces First Quarter 2020 Financial Results and Corporate Updates
-
UPDATE – Amicus Therapeutics Announces Upcoming Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting
-
Amicus Therapeutics Announces Upcoming Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting
-
Amicus Therapeutics to Announce First Quarter 2020 Financial Results on May 7, 2020
-
Amicus Therapeutics (FOLD) Reiterates Business Continuity, FY20 Strategic Priorities; Highlights Response to COVID-19 Outbreak
-
Amicus Therapeutics Confirms Business Continuity, 2020 Strategic Priorities and Announces Proactive Efforts to Support Public Health Initiatives, Patients & Employees
-
Amicus Opens New Global Research and Gene Therapy Center of Excellence in Philadelphia
-
Amicus Therapeutics Announces Full-Year 2019 Financial Results and 2020 Corporate Updates
-
Amicus Therapeutics to Present at the Cowen & Company 40th Annual Health Care Conference
-
Amicus Therapeutics to Announce Full-Year 2019 Financial Results on March 2, 2020
-
Amicus Therapeutics Announces Presentations and Posters at 16th Annual WORLDSymposium™ 2020
-
Amicus Therapeutics Provides Full-Year 2020 Strategic Outlook and Financial Guidance
-
Amicus Therapeutics (FOLD) Announces Preliminary 2019 Galafold Revenue, Exceeding Upper End of Prior Guidance
-
Amicus Therapeutics Announces Preliminary 2019 Galafold Revenue - Exceeding Upper End of Prior Guidance
-
Amicus Therapeutics (FOLD) Provides Updates on Clinical, Regulatory and Manufacturing Advancements for AT-GAA for Pompe Disease
-
Amicus Therapeutics Provides Updates on Clinical, Regulatory and Manufacturing Advancements for AT-GAA for Pompe Disease
-
Amicus Therapeutics Announces Third Quarter 2019 Financial Results and Corporate Updates
-
Amicus Therapeutics to Announce Third Quarter 2019 Financial Results on November 11, 2019

